Journal: Bioactive Materials

Article Title: LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer

doi: 10.1016/j.bioactmat.2025.12.015

Figure Lengend Snippet: Analysis of tumor microenvironment and systemic safety evaluation. (A) Representative immunofluorescence staining of tumor tissues from different treatment groups, showing CD31 + blood vessels (red), CD206 + M2 macrophages (green), and DAPI (blue) for nuclei. Scale bar = 100 μm. (B) Representative H&E-stained histological sections of major organs (heart, liver, spleen, lungs, and kidneys). Scale bar = 200 μm. (C) Quantitative analysis of microvessel density (MVD) based on CD31-positive areas. (D) Quantitative analysis of CD206-positive areas. (E) Statistical summary of the percentage of F4/80 + CD86 + cells within CD45 + cells in tumor tissues, as determined by flow cytometry. (F) Quantitative analysis of the HIF-1α-positive area percentage in tumor tissues from different groups. REG@LF means REG@LFHA NPs, REG@LFHA means REG@LFHA NPs. All statistical data are represented as mean ± SD (n = 3; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

Article Snippet: Rabbit anti-mouse CD31 polyclonal antibody and rabbit anti-mouse CD206 polyclonal antibody were acquired from Servicebio (Wuhan, China).

Techniques: Immunofluorescence, Staining, Flow Cytometry